• Agreement combines Baird Medical's clinical, regulatory, and global commercialization expertise with Alpmed's leadership in IRE technology

     
  • Collaboration will advance technology development, global regulatory approvals, commercialization, and clinical adoption across key international markets, including the United States
     

NEW YORK, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Ltd. (NASDAQ:BDMD) ("Baird Medical" or the "Company") and Tianjin Yuanshan Medical Technology Co., Ltd., operating under the Alpmed brand ("Alpmed"), a China-based innovator in irreversible electroporation ("IRE") technology, announced the signing of a strategic cooperation agreement to establish a long-term partnership focused on global development and commercialization of next-generation IRE technologies.

The partnership represents an important strategic milestone for Baird Medical, as the Company expands beyond its market-leading microwave ablation (MWA) system for benign thyroid nodules and broadens its portfolio of minimally invasive technologies targeting key markets worldwide.

Under the partnership, the companies will initially collaborate on IRE, an advanced, non-thermal ablation technology that uses electrical pulses to destroy targeted tissue while preserving surrounding critical structures, such as blood vessels and nerves. The collaboration will combine Alpmed's expertise in IRE innovation with Baird Medical's regulatory and global commercialization capabilities, with the goal of advancing next-generation precision ablation solutions and exploring opportunities to expand the partnership beyond IRE.

Baird Medical and Alpmed plan to submit a 510(k) application for the first co-developed product to the U.S. Food and Drug Administration (FDA) by the end of 2026, with the potential to receive regulatory clearance in 2027. The first device is intended for the ablation of soft tissue solid tumors in the liver, breast, thyroid, and prostate. Baird Medical will lead the global regulatory approval processes, including in the U.S., and holds worldwide commercialization rights for this IRE product.